Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of NEXAGON (lufepirsen ophthalmic gel) for persistent corneal epithelial defects; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• NEXAGON

Snippet

Sponsor: Glaukos Corporation | Conditions: Persistent Corneal Epithelial Defect | Phase 2 | Status: RECRUITING